Showing results (171-180 of 321) with videos related to

Sort By:
Pageof 33
Bioorganic & Medicinal Chemistry Letters|September 18, 2007
Arene cis-dihydrodiols: useful precursors for the preparation of analogues of the anti-tumour agent, 2-crotonyloxymethyl-(4R,5R,6R)-4,5,6-trihydroxycyclohex-2-enone (COTC)Claire L Arthurs, James Raftery, Helen L Whitby, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1992
Magnetic resonance spectroscopy studies on experimental murine and human tumors: comparison of changes in phosphorus metabolism with induced changes in vascular volumeG E Adams, J C Bremner, C J Counsell, et al.
Molecular Cancer Therapeutics|November 18, 2011
In silico screening reveals structurally diverse, nanomolar inhibitors of NQO2 that are functionally active in cells and can modulate NF-κB signalingKaren A Nolan, Mark S Dunstan, Mary C Caraher, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1992
The response of spontaneous and transplantable murine tumors to vasoactive agents measured by 31P magnetic resonance spectroscopyP J Wood, I J Stratford, J M Sansom, et al.
International Journal of Radiation Oncology, Biology, Physics|July 1, 1991
Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in miceS Cole, I J Stratford, J Bowler, et al.
British Journal of Cancer|December 10, 1999
Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?E C Chinje, A V Patterson, M P Saunders, et al.
European Journal of Cancer (Oxford, England : 1990)|February 14, 2004
Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection; results of EORTC Translational Research Fund studiesR J Oliver, R T M Woodwards, P Sloan, et al.
Biochemical Pharmacology|July 19, 1994
Reversal of P-glycoprotein-mediated multidrug resistance by pure anti-oestrogens and novel tamoxifen derivativesJ Kirk, S K Syed, A L Harris, et al.
Anti-Cancer Drugs|June 1, 1994
Cyclopropamitosenes: novel bioreductive anticancer agents--mechanism of action and enzymic reductionC J Moody, N O'Sullivan, I J Stratford, et al.
British Journal of Cancer|November 1, 1995
Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233)A V Patterson, H M Barham, E C Chinje, et al.
Pageof 33